Clavicular Stack Results: Week-by-Week Timeline
What to realistically expect from Retatrutide + BPC-157 — week by week, based on Phase 2 clinical data and BPC-157 research. No hype, just timelines.
Research Information Only. Retatrutide and BPC-157 are research peptides not approved for human use. Timelines on this page are derived from Phase 2 clinical trial data (NEJM, DOI: 10.1056/NEJMoa2301972) and preclinical BPC-157 literature — they are not medical advice. Individual results vary significantly. Consult a qualified healthcare professional before using any peptide.
Key Numbers From the Research
Week 4
Appetite suppression becomes noticeable
Retatrutide Phase 2 participant reports
Week 8–12
Visible fat reduction begins
Face, midsection changes observed
24.2%
Max weight reduction in Phase 2
48 wks, 12mg, NEJM (n=338)
48 weeks
Full Phase 2 trial duration
Eli Lilly / NEJM 2023
What Is the Clavicular Stack?
Clavicular — the looksmaxxing streamer who made peptides mainstream — runs a two-peptide core protocol built around aggressive fat loss and rapid physical transformation.
Retatrutide
Triple GLP-1/GIP/Glucagon agonist
The engine of the stack. Retatrutide simultaneously activates three metabolic receptors, producing more aggressive appetite suppression and fat oxidation than any single- or dual-agonist peptide. Phase 2 data showed up to -24.2% body weight over 48 weeks at 12mg.
BPC-157
15-amino-acid healing pentadecapeptide
The support peptide. BPC-157 is stacked alongside Retatrutide to manage GI adaptation (GLP-1 agonists cause nausea in 38–43% of users), protect gut integrity, and accelerate recovery from any training or inflammation. It's not driving fat loss directly — it's keeping the protocol sustainable.
The synergy is straightforward: Retatrutide does the heavy lifting on body recomposition while BPC-157 reduces the friction of getting there — faster adaptation, better gut tolerance, and maintained recovery capacity even in a caloric deficit.
Week-by-Week Results Timeline
What the research data and community reports suggest you can realistically expect — phase by phase.
Minimal Visible Change — GI Adaptation
The first two weeks are about your body learning how to handle Retatrutide. At a lowstarting dose, visible changes are essentially non-existent — this is not a failure, it is the protocol working correctly. Nausea is common in weeks 1–2 as GLP-1 receptor activity slows gastric emptying. GI side effects were reported in 38–43% of Phase 2 participants at therapeutic doses.
Retatrutide
Stay at low starting dose. Do not rush titration.
BPC-157
May speed gut adaptation and reduce nausea duration.
Visible Change
Essentially none. Scale may fluctuate.
Appetite Suppression Kicks In
This is typically the first milestone users notice. The triple-agonist mechanism of Retatrutide — particularly GLP-1 and GIP receptor activity — begins producing meaningful appetite suppression around week 3. You eat less without effort. Hunger cues feel different. The scale starts moving as your body begins adjusting to a new caloric intake baseline. Body weight reduction at this stage is typically modest (1–3%), but the subjective experience of reduced hunger is a clear signal the peptide is working.
Visible Changes Begin
Weeks 5–8 are where the looksmaxxing angle starts to pay off. Fat reduction becomes visible — typically first in the face (reduced puffiness, sharper jaw definition) and midsection. Energy levels tend to stabilize as the body adapts to lower caloric intake. BPC-157's anti-inflammatory and recovery properties become relevant here, especially if you're training — reduced recovery time and joint comfort are commonly reported. Based on Phase 2 kinetics, participants in this window were typically around 4–8% body weight reduction.
Fat Reduction Pattern
Face sharpens first. Subcutaneous fat in the midsection follows. Visceral fat reduction (accelerated by glucagon receptor activity) may not be visually obvious yet but is already underway.
BPC-157 Role
Reduced inflammation supports maintained training intensity. Gut adaptation is largely complete. Recovery between sessions notably faster for most users.
Others Start Noticing
At the 3-month mark, body composition shifts are significant enough that people in your life notice. This is the window that produces the "before and after" photos that circulate in the looksmaxxing community. Phase 2 data places participants at roughly 10–15% body weight reduction by week 12, depending on starting dose. Strength maintenance becomes increasingly important — a significant caloric deficit risks lean mass alongside fat. Consider titrating your Retatrutide dose upward if GI side effects have resolved and you want to accelerate progress.
Dosing Note
Phase 2 participants saw the most significant weight loss at 8mg and 12mg doses. Low-dose responders (2–4mg) also showed meaningful results. Titration should be gradual — rushing to maximum dose increases GI side effect risk.
Peak Body Recomposition Window
Months 3–6 represent the window in which Retatrutide produces the most dramatic results relative to baseline. Based on Phase 2 data, participants at 12mg in this window were in the -15% to -24.2% body weight reduction range. The glucagon receptor component — unique to Retatrutide — continues driving hepatic lipid oxidation and energy expenditure, meaning fat loss continues even as the body adapts to reduced food intake. Body recomposition is well underway, and the looksmaxxing payoff (facial leanness, definition, jaw structure) is at its most visible.
-15%
Conservative estimate at month 3–4
Lower dose / slower titration
-20%
Typical range at month 5–6
8–12mg at Phase 2 doses
-24.2%
Phase 2 maximum at 48 wks
NEJM 2023, 12mg (n=338)
Maintenance Phase or Continued Progress
Beyond 6 months, the trajectory splits based on dose and goals. At therapeutic doses (8–12mg), continued fat loss is possible up to the 48-week mark where Phase 2 data ended. At lower maintenance doses, many users shift focus toward preserving their recomposition results — keeping appetite suppression in place without driving further deficit. BPC-157 continues to provide recovery support. The looksmaxxing community refers to this phase as "locking in" the physique changes achieved during the primary protocol window.
Ready to Start the Protocol?
Get Retatrutide + BPC-157 from Clav Tides and begin the stack that drives the results above.
Managing Expectations: This Is Research Data
The timeline above is derived from Phase 2 clinical trial data published in the New England Journal of Medicine — not influencer anecdotes. That data is meaningful and robust (338 participants, 48 weeks, multiple dosing cohorts). But it also represents medically supervised research with controlled conditions.
What the Data Supports
- Meaningful appetite suppression beginning around week 3–4
- Progressive, dose-dependent body weight reduction
- Up to -24.2% body weight over 48 weeks at 12mg
- Significant visceral and liver fat reduction
What Varies Individually
- How quickly appetite suppression becomes noticeable
- Severity of GI adaptation (nausea varies widely)
- Rate of visual change (starting body composition matters)
- Where fat is lost first (genetic fat distribution)
The BPC-157 Factor: Why Adding It Matters
BPC-157 is not an afterthought in this stack — it's what makes the protocol sustainable. Here is why Clavicular pairs it with Retatrutide rather than running Retatrutide alone.
Gut Protection During GLP-1 Adaptation
GLP-1 receptor agonists slow gastric emptying, which is why 38–43% of Retatrutide Phase 2 participants experienced nausea. BPC-157 exerts gastroprotective effects through the VEGFR2/PI3K/Akt/eNOS pathway — the same mechanism studied by Dr. Predrag Sikiric's lab across 36+ publications. Users report faster adaptation and reduced GI discomfort duration when running both peptides simultaneously.
Recovery Maintenance in a Deficit
Training in a significant caloric deficit degrades recovery capacity. BPC-157's pro-angiogenic effects (FAK-paxillin and Src-caveolin-1-eNOS pathways) accelerate tissue repair and reduce recovery time between sessions. For the looksmaxxing goal of maintaining or building muscle definition while losing fat, this is meaningful — it allows higher training volume than most aggressive cuts permit.
Faster Adaptation = Earlier Timeline Entry
The biggest practical benefit: if BPC-157 shortens the GI adaptation window in weeks 1–2, you can titrate Retatrutide upward sooner and reach therapeutic appetite suppression doses earlier. This may shift the timeline by 1–3 weeks, compressing the path from "adjustment" to "visible changes."
What Factors Affect Your Results
The Phase 2 data is an average. Your actual timeline will depend on several variables.
Starting Body Composition
Higher starting body fat percentage typically means faster early visible change. Those closer to lean already need more time to see meaningful visual shifts.
Retatrutide Dose
Phase 2 showed clear dose-response: 2mg < 4mg < 8mg < 12mg in terms of weight loss. Higher dose accelerates the timeline but increases GI side effect risk.
Training Protocol
Resistance training while on Retatrutide significantly changes body composition outcomes — muscle preservation affects the visual result even if scale weight is similar.
Titration Speed
How quickly you ramp dose affects both the timeline and your GI adaptation experience. Slower titration means gentler adaptation but a delayed peak.
BPC-157 Inclusion
Running BPC-157 alongside Retatrutide may compress the adaptation window, allowing faster dose escalation and an earlier transition to the visible results phase.
Individual Receptor Sensitivity
GLP-1, GIP, and glucagon receptor sensitivity varies between individuals. Some respond dramatically at low doses; others need higher doses to see the same appetite effect.
Start the Stack. Follow the Timeline.
The research is clear on what Retatrutide + BPC-157 can do over 48 weeks. The only variable left is when you start. Browse all stacks and pricing at our trusted research supplier.